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Beijing Institute of Microbiology and Epidemiology, Beijing and 4) Graduate School of Anhui Medical University, Hefei, PR ChinaAbstractThe wide epidemic and high case fatality rate have made severe fever with thrombocytopenia syndrome (SFTS) a signiﬁcant public health
problem. The diagnosis and discrimination of SFTS virus (SFTSV) infection at an early stage of the disease is important for treatment
choice. A prospective study was performed in an SFTS reference hospital during 2011–2013. Suspected SFTS patients were recruited
and prospectively observed. Comparison between SFTSV-positive and -negative patients was made to identify the parameters that were
related to positive detection by discriminant and classiﬁcation tree analysis. A total of 538 SFTSV-positive and 396 negative patients were
recruited and observed. Multiple logistic regression models demonstrated the signiﬁcant parameters associated with positive detection,
including decreased platelet counts and elevated aspartate aminotransferase (AST) level during the ﬁrst stage (1~4 days), decreased white
blood cell and platelet counts, elevated creatine kinase (CK) and AST levels during the second stage (5~7 days), and older age, decreased
consciousness and elevated CK and AST during the third stage (8–11 days). The classiﬁcation trees disclosed that the signiﬁcant
predictors for positive SFTSV detection were AST >50.6 U/L and AST/alanine transaminase (ALT) >1.3 at the ﬁrst stage, CK >257 U/L
or 57.7 U/L < CK 98.5 U/L with AST/ALT >1.6 at the second stage, as well as CK >630.7 U/L or 114.3 U/L < CK 630.7 U/L with
decreased consciousness at the third stage. In making the clinically probable diagnosis of SFTS, the supplementation of AST and CK
evaluations might remarkably improve the diagnostic capacity of routine laboratory tests, while the leukopenia is of limited use.
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5These authors contributed equally to this work.IntroductionSevere fever with thrombocytopenia syndrome (SFTS) is an
emerging infectious disease, ﬁrst identiﬁed in central China in
2009, caused by a novel bunyavirus classiﬁed as a new member
of genus Phlebovirus, family Bunyaviridae [1]. By July 2013, SFTS
cases had been reported in at least 15 provinces of mainlandMicrobiol Infect 2015; 21: 204.e1–204.e7
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p://dx.doi.org/10.1016/j.cmi.2014.07.012China [2–6]. SFTS-like patients had been reported in Missouri,
United States [7,8]. In Japan and Korea, cases with SFTS virus
(SFTSV) infection were reported recently and none of them had
overseas travel history [9,10], suggesting its expanded distri-
bution outside of China.
Based on current knowledge, person-to-person trans-
mission of SFTSV through blood contact and other potential
unknown transmission modes were identiﬁed [11–14].
Therefore, the diagnosis and discrimination of SFTSV infection
at an early stage of the disease is extremely important in order
to adopt proper response in preventing nosocomial infection.
However, early diagnosis of SFTSV infection was challenged by
the nonspeciﬁc clinical presentation (mostly fever and gastro-
intestinal symptoms) and laboratory ﬁndings (mostlyiety of Clinical Microbiology and Infectious Diseases
CMI Lu et al. Discrimination of novel bunyavirus infection 204.e2thrombocytopenia and leukocytopenia) that were indistin-
guishable from other viral infections [1,15,16]. Given the
nonspeciﬁc presentation of SFTS, the Chinese Ministry of
Health proposed a suspected case deﬁnition of combined
clinical features (fever), epidemiological features (previous ﬁeld
activity in SFTS-endemic areas or a recent tick bite history) and
laboratory abnormality (thrombocytopenia and leukocytope-
nia) [17]. However, only 52% of conﬁrmed patients had re-
ported tick bite history, according to previous investigation
[18], therefore, in previously unrecognized endemic regions,
the addition of this epidemiological information into diagnosis
criteria might not help to increase the diagnostic accuracy.
Even in SFTS-endemic areas, these combined criteria are still
nonspeciﬁc, since other tick-borne aetiologies, like Anaplasma
phagocytophilum and Rickettsia species, which present highly
similar clinical and laboratory features, were also prevalent in
the natural environment [19–23].
On the other hand, the laboratory conﬁrmation of SFTSV
infection could be attained by either positive PCR detection
or seroconversion for SFTSV antibody [1,16,24,25]. The lim-
itation of applying these techniques, however, is that most of
the SFTS occurred in rural areas where RT-PCR tests of
SFTSV infection are rarely performed and serological results
need to be determined by at least 2 weeks apart. Therefore,
initial assessment of potential SFTS cases continues to rely
heavily on clinical factors, especially in SFTS-endemic rural
areas.
The present study is intended to assess the ability of clinical
features and laboratory tests that were routinely performed in
clinical practice in distinguishing SFTSV infection; these pa-
rameters could be used at the early stage of hospitalization to
guide an appropriate prevention strategy and timely treatment
administration.MethodsDesign, setting and patients
The study was performed in an SFTS reference hospital in
Xinyang administrative district of Henan Province from 2011 to
2013. Xinyang is the endemic area in China most severely
afﬂicted with SFTS, with about one-third of the total SFTS cases
in China reported from 2011 to 2012 [26]. The suspected SFTS
patients were recruited according to the national guidelines
with minor modiﬁcation, that is, fever of unknown reason,
clinically diagnosed thrombocytopenia or leukopenia, with
previous ﬁeld activity or an exposure history to ticks. Patients
with cancer, hepatitis or known comorbidities with similar
laboratory abnormalities were excluded.© 2014 Clinical Microbiology and Infection published by Elsevier Ltd on behalf of EuClinical and laboratory evaluations
Serum samples were collected from all suspected patients on
admission and at regular intervals during the hospitalization and
after convalescence. Detection of SFTSV RNA by real-time RT-
PCR and SFTSV-speciﬁc IgM and IgG antibodies by ELISA were
performed as previously described [16]. A conﬁrmed SFTSV-
positive patient was deﬁned as meeting one or more of the
following criteria: i) detection of SFTSV-speciﬁc RNA for
samples collected during the hospitalization, or ii) serocon-
version or a more-than fourfold increase of antibody titres
between two sera samples collected at least 2 weeks apart. An
SFTSV-negative case was deﬁned as negative results for both
SFTSV-speciﬁc RNA and lacking seroconversion or a more-
than fourfold increase of antibody titres. In the absence of
convalescence sera samples, negative results for both SFTSV-
speciﬁc RNA and IgM antibody tests during the hospitalization
were used.
Source of information and data collection
We performed a chart review of all recruited patients to collect
the information on demographic characteristics, symptoms and
signs, and clinical physical examination, and prospectively
collected the hematologic and biochemical tests and treatment
regimens, from disease onset until hospital discharge. These
data were drawn from the medical database by a group of
trained physicians using a standardized format, which were
further reviewed for accuracy and consistency by a group of
epidemiologists. The human ethics committee of the hospital
approved the research protocol, and all participants provided
written informed consent.
Statistical analysis
Descriptive statistics were performed with continuous vari-
ables estimated with median and range, and categorical variables
summarized as frequencies and proportions. To determine the
difference between the positive and negative groups, categorical
variables were compared with χ2 or Fisher exact tests and
continuous variables with two-sample Wilcoxon rank-sum test.
Since there are various hospital admission delays, the study is
designed to identify the parameters for discrimination at
various disease phases. At ﬁrst step, the disease phases were
deﬁned in reﬂecting distinct characteristics. Brieﬂy, three clin-
ical phases were randomly categorized and each evaluated
parameter was compared among three phases for positive and
negative cases, respectively. The grouping modes that produced
the highest number of signiﬁcant differences among three
clinical phases were used to deﬁne the clinical phases. There-
after, at each clinical stage, the dynamic data of clinical param-
eters from disease onset until hospital discharge variables wereropean Society of Clinical Microbiology and Infectious Diseases, CMI, 21, 204.e1–204.e7
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signiﬁcant variables in the univariate analysis (p <0.05) were
entered into a multivariate logistic regression model to deter-
mine the appropriate parameters that could classify the subjects
into positive and negative groups. In order to control the co-
linearities, the continuous variables were divided into the cat-
egorical variables (Supplementary Table 1). Receiver operator
characteristic curves were constructed and the area under the
receiver operator characteristic curve (AUC) was calculated as
a measure of discriminative ability. Higher AUC values were
considered to demonstrate better discriminatory abilities as
follows: excellent discrimination with AUC 0.90, good
discrimination with 0.70  AUC <0.90, fair discrimination with
0.50  AUC <0.70, and poor discrimination with AUC <0.50.
The same batch of variables was additionally put into the clas-
siﬁcation tree and used to identify the factors predictive of
SFTSV-positive detection with a chi-square automatic interac-
tion detection (CHAID) model.
All statistical analyses were performed using SAS 9.3 soft-
ware (SAS Institute, Cary, NC, USA) and p <0.05 was consid-
ered statistically signiﬁcant.TABLE 1. Demographic and clinical characteristics of SFTSV-Results
positive vs. SFTSV-negative patients on admission
Characteristic
All SFTS
patients
(n [ 934)
SFTSV
p
Positive
(n [ 538)
Negative
(n [ 396)
Demographic characteristics
Male gender/n (%) 393 (42.1) 229 (42.6) 164 (41.4) 0.725d
Agea,b/years, mean (SD) 57.6 ± 13.8 59.5 ± 12.7 55.0 ± 14.8 <0.001e
Days delaya/median
(range)
6 (1–25) 6 (1–24) 5 (1-23) <0.001f
Presence of underlying
conditions
n (%) of
Patients
Diabetes 31 (3.3) 20 (3.7) 11 (2.8) 0.428d
Hypertension 54 (5.8) 29 (5.4) 25 (6.3) 0.550d
Clinical manifestations
Fever >38°Ca 918 (98.3) 533 (99.1) 385 (97.2) 0.031d
Gastrointestinal
syndromes
883 (94.5) 514 (95.5) 369 (93.2) 0.117d
Feeblea 866 (92.7) 507 (94.2) 359 (90.7) 0.037d
Myalgias* 654 (70.0) 401 (74.5) 253 (63.9) <0.001d
Lymphadenopathya,b 383 (41.0) 247 (45.9) 136 (34.3) <0.001d
Arthralgias 316 (33.8) 173 (32.2) 143 (36.1) 0.207d
Cougha,b 257 (27.5) 177 (32.9) 80 (20.2) <0.001d
Sputum productiona 205 (22.0) 139 (25.8) 66 (16.7) <0.001d
Decreased level of
consciousnessa,b,c
182 (19.5) 131 (24.4) 51 (12.9) <0.001d
Dizzya 182 (19.5) 117 (21.8) 65 (16.4) 0.042d
Headache 164 (17.6) 102 (19.0) 62 (15.7) 0.190d
Dyspnoeaa,b 57 (6.1) 45 (8.4) 12 (3.0) <0.001d
Data are n (%) of patients, mean value ± standard deviation, or median (range).
SFTSV, severe fever with thrombocytopenia syndrome virus.
aThe variables were entered into the multiple logistic regression analysis.
bWith signiﬁcant association by performing multiple logistic regression analysis with
all the variables included. The adjusted OR (95% CI) was estimated to be 1.019
(1.009–1.029) for age, 1.618 (1.227–2.134) for lymphadenopathy, 1.504
(1.084–2.087) for cough, 1.660 (1.146–2.405) for decreased level of consciousness
and 2.315 (1.161–4.618) for dyspnea.
cIncludes presence of apathetic facial expressions, dysphoria, convulsion, drowsi-
ness, blurred mind, or coma.
dBy means of the χ2 test.
eBy means of the t test.
fBy means of a nonparametric test.Patients
From 2011 through 2013, a total of 1127 patients who met the
criteria for suspected SFTS cases were hospitalized in the 154
Hospital. Altogether, 538 (47.7%) were conﬁrmed to be
infected with SFTSV (463 patients with positive RT-PCR
detection, 75 patients with fourfold increase of IgG antibody).
A total of 396 (35.1%) patients were determined to be SFTSV
negative by both negative RT-PCR and lack of seroconversion
of IgG antibody after convalescence (181 patients), and both
negative RT-PCR and IgM detection (215 patients).
The patients were hospitalized, with a median hospital stay of
9 days (range 2–26 days). A total of 28 parameters, including 12
clinical manifestations (fever >38°C, gastrointestinal syn-
dromes, weakness, myalgias, lymphadenopathy, arthralgias,
cough, sputum production, decreased level of consciousness,
dizziness, headache, dyspnoea) and 16 routine laboratory pa-
rameters, including platelet, white blood cell (WBC) count,
neutrophil percentage, lymphocyte percentage, haemoglobin,
alanine transaminase (ALT), aspartate aminotransferase (AST),
AST/ALT ratio, lactate dehydrogenase (LDH), creatine kinase
(CK), albumin (ALB), alkaline phosphatase, gamma-glutamyl
transpeptidase, blood urea nitrogen, creatinine and amylase,
were obtained during the whole hospitalization. A total of 4441
consecutive evaluations were obtained from the 934 patients,© 2014 Clinical Microbiology and Infection published by Elsevier Ltd on behalf of European Socwith a median of four (range 2–10) evaluations obtained for
each patient.
Demographic and clinical characteristics of SFTSV
For comparison between the two groups, the gender distri-
bution was comparable, while age and the delay days from
disease onset to admission were signiﬁcantly different (both p
<0.001). Regarding clinical therapy, ribavirin and doxycycline
administration composed major therapies, which were highly
comparable between the two groups (Supplementary Table 2).
The mortality rate in SFTSV-infected patients was signiﬁcantly
higher than that of SFTSV-negative patients (16.2% vs. 8.1%; p
<0.001).
The clinical manifestations on hospital admission were pre-
sented separately for SFTSV-infected patients and SFTSV-
negative patients (Table 1). All clinical manifestations, except
gastrointestinal syndromes, arthralgias and headache, were
signiﬁcantly different between the two groups by univariate
analysis (Table 1). By performing multiple logistic regression
analysis, signiﬁcant association remained for four clinical pa-
rameters (lymphadenopathy, cough, decreased level ofiety of Clinical Microbiology and Infectious Diseases, CMI, 21, 204.e1–204.e7
TABLE 2. The multiple analysis for the factors associated with SFTSV infection during three stages
Factors
First stage Second stage Third stage
OR (95% CI) p OR (95% CI) p OR (95% CI) p
Age NA NA 1.032 (1.005–1.060) 0.084
Decreased consciousness NA NA 2.588 (1.004–6.666) 0.049
WBC NA 1.927 (1.217–3.051) 0.005 NA
Platelet 2.116 (1.227–3.648) 0.007 1.535 (1.010–2.331) 0.045 NA
CK NA 1.602 (1.080–2.375) 0.019 2.756 (1.509–5.032) 0.001
AST 2.059 (1.135–3.737) 0.018 2.109 (1.364–3.262) <0.001 2.331 (1.132–4.800) 0.022
AST, aspartate aminotransferase; CK, creatine kinase; SFTSV, severe fever with thrombocytopenia syndrome virus; WBC, white blood cell.
Note: NA means that the factor was not entered into the model.
CMI Lu et al. Discrimination of novel bunyavirus infection 204.e4consciousness and dyspnoea), after adjusting the effect from
age, gender, delay of hospital admission, and presence of un-
derlying conditions. The adjusted OR (95% CI) was estimated
to be 1.618 (1.227–2.134) for lymphadenopathy, 1.504
(1.084–2.087) for cough, 1.660 (1.146–2.405) for decreased
level of consciousness, and 2.315 (1.161–4.618) for dyspnoea,
respectively. The AUC for the logistic regression model was
calculated to be 0.652, which was considered to have fair
discrimination ability.
Laboratory parameters proﬁle and clinical phase
deﬁnition
The dynamic patterns of 17 laboratory parameters were
delineated and compared between the SFTSV-positive andFIG. 1. The ﬂow diagram of
discriminating SFTSV infection among
clinically diagnosed SFTS patients.
ALT, alanine transaminase; AST,
aspartate aminotransferase; CK,
creatine kinase; SFTS, severe fever
with thrombocytopenia syndrome;
SFTSV, SFTS virus.
© 2014 Clinical Microbiology and Infection published by Elsevier Ltd on behalf of EuSFTSV-negative groups through the whole hospitalization
(Supplementary Fig. 1). When we divided the clinical stages into
1~4 days, 5~7 days and 8~11 days post infection, a distinct
pattern of the laboratory parameters could be observed across
three stages. By applying analysis of variance or nonparametric
test, all the biochemical parameters showed signiﬁcant differ-
ences among three stages in the SFTSV-positive group; all but
two parameters (blood urea nitrogen and creatinine) demon-
strated signiﬁcant differences among three stages in the positive
group (Supplementary Table 3). This represented the grouping
method, with the highest number of indicators demonstrating
signiﬁcant differences among three clinical phases, and the
clinical progression was accordingly divided into early stage
(1~4 days), middle stage (5~7 days) and late stage (8~11 days).ropean Society of Clinical Microbiology and Infectious Diseases, CMI, 21, 204.e1–204.e7
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patients at different clinical stages
By univariate analysis, age, laboratory tests of platelet counts,
ALT, AST, LDH, CK and ALB levels were signiﬁcantly different
between the positive and negative groups at the ﬁrst stage
(Supplementary Table 4). Nine parameters at the second stage
(neutrophils percentage, lymphocyte percent, platelet counts,
WBC, ALT, AST, LDH, CK and ALB) and seven parameters at
the third stage (lymphocytes percentage, haemoglobin, ALT,
AST, LDH, CK and ALB) differed signiﬁcantly between the two
groups.
These signiﬁcant parameters at each stage were entered into
multiple logistic regression models, together with the age,
clinical manifestations of lymphadenopathy, decreased level of
consciousness, dyspnoea and cough to analyse the effects
separately. It is demonstrated that the decreased platelet counts
and elevated AST level during the ﬁrst stage; decreased WBC
and platelet counts, elevated CK and AST levels during the
second stage; and older age, decreased consciousness, elevated
CK and AST during the third stage were signiﬁcantly associated
with SFTSV infection (Table 2). The AUCs for the three logistic
regression models were calculated to be 0.717, 0.748, and
0.803, respectively, which were all considered to offer good
discrimination ability. The values of predicted index for the
three stages are listed in Supplementary Table 5.
The classiﬁcation trees were used to explore the high-risk
population for SFTSV infection. The results disclosed that the
signiﬁcant predictors for positive SFTSV detection were AST
>50.6 U/L and AST/ALT >1.3 at the ﬁrst stage, CK >257 U/L or
57.7 U/L < CK 98.5 U/L with AST/ALT >1.6 at the second
stage, as well as CK >630.7 U/L or 114.3 U/L < CK 630.7 U/L
with decreased consciousness at the third stage. The classiﬁ-
cation tree node estimations are displayed in Supplementary
Figs. 2–4.DiscussionStudies have been published describing the clinical and labora-
tory features of SFTS, which were based on the cross-sectional
description without performing adequate statistical analysis
[1,27,28]. Based on the comparison between SFTSV-positive
and -negative patients, we increased the clinical diagnosis
criteria of SFTS patients combining clinical and laboratory
characteristics (Fig. 1). In brief, relying only on symptoms and
syndromes, a clinically suspected patient in an endemic area
who presented with lymphadenopathy, cough, decreased level
of consciousness and dyspnoea could be determined as prob-
ably SFTSV infected. After the laboratory tests were available,
abnormal AST and ALT within 4 days after disease; abnormal© 2014 Clinical Microbiology and Infection published by Elsevier Ltd on behalf of European SocAST, ALT and CK between 5 and 7 days; and clinical presen-
tation of decreased consciousness and abnormal CK when
exceeding 7 days after disease onset could be used in making
diagnosis of probable SFTSV infection.
These ﬁndings could inﬂuence the diagnosis criteria in two
aspects. Firstly, according to the current results, only 70.1% of
the conﬁrmed patients presented both thrombocytopenia and
leukopenia at the acute phase. Therefore, if the initial clinical
diagnosis criteria of both thrombocytopenia and leukopenia
were used as deﬁned in 2010 (http://www.moh.gov.cn/
publicﬁles/business/htmlﬁles/wsb/pwsyw/201009/49245.htm)
[3,29], almost 30% of the patients who presented thrombocy-
topenia or leukopenia, instead of both, might be missed.
Another signiﬁcant ﬁnding is that in previous diagnosis criteria,
only hematologic evaluations (WBC and platelet counts) were
used as indicators in deﬁning a suspected SFTS case. According
to our results, the AST and CK can be useful indicators in
evaluating patients with nonspeciﬁc presentations, especially in
early infection when leukopenia was untypical, and in late
infection when platelet and WBC counts start to recover.
These parameters reﬂecting the hepatic and renal injury might
constitute valuable supplements in enhancing discrimination
power of identifying SFTSV patients. In contrast, leukopenia is
of limited use in the differential recognition of SFTSV patients,
in both early and late disease phases.
According to the current study, the syndrome of fever >38°
C, gastrointestinal syndromes, weakness and myalgia were the
most commonly seen syndromes, presenting in more than half
of the SFTSV-infected patients; however, these syndromes
were nonspeciﬁc and could be seen in SFTS-negative patients
with comparable frequencies. Other uncommonly seen syn-
dromes, including lymphadenopathy, cough, decreased level of
consciousness and dyspnoea, on the other hand, were signiﬁ-
cantly associated with positive SFTSV detection. However,
these syndromes could predict only 65.2% of illnesses that were
determined to be SFTSV positive, and therefore should be
cautiously used, merely before performing laboratory tests.
Given that fever and other complaints might disappear on drug
use, we recommend including only clinical syndromes at the
early disease phase, instead of the serial observation, into
analysis.
We acknowledge that the false negativity might exist due to
the sensitivity of the detection methods. However, even though
these patients were missed, their low viremia level posed less
threat of human-to-human transmission. They were also less
likely to develop severe disease, considering the highly positive
correlation between viral loads and disease severity in previous
studies [15,28,30]. Despite this notion, the proportion of low
sensitivity and other possible causal agents among the SFTSV-
negative patients remained unknown, which needs furtheriety of Clinical Microbiology and Infectious Diseases, CMI, 21, 204.e1–204.e7
CMI Lu et al. Discrimination of novel bunyavirus infection 204.e6investigation in the future. Another limitation exists, as the
study was carried out in an endemic region where potential
vector or animal host exposure is fairly common. The diagnosis
criteria might result in fairly high odds of a false-positive result
in nonendemic regions, and therefore, might be of limited use.
Finally, the measurement of serum concentrations of enzymes
as discrimination criteria should be used cautiously, since the
methods and normal ranges vary among laboratories.
Taken together, we conclude that it is possible to predict
SFTSV infection on the basis of clinical presentation and routine
blood tests. In rural areas where RT-PCR testing is less likely,
the acquirement and analysis of these indicators might be of
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